CLINICAL_TRIALS
trial_result
· 2021-05-14
Clinical Trial Update: Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer [Phase 2]
Summary
Phase 2 trial of NRX 194204 in castration- and taxane-resistant prostate cancer has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Io Therapeutics | Conditions: Castration Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-05-14